Error loading player: No playable sources found
Welcome and Session I: Bioassays for Cell and Gene Therapies
Date
April 20, 2021
This product is not available for individual purchase, but it is available as part of the following products:
Session Chairs
Kite, a Gilead Company
AstraZeneca BioVentures
Precision Biosciences
Session Speakers
Biogen
Sanofi
Kite, a Gilead Company
Bristol-Myers Squibb Company
Related Products
Session IV: Bioassays for Vaccines and Antibody Therapies with Discussion
The pandemic of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has significantly impacted the lives of the global human population…
Keynote Presentation - Bioassay Evolution - Where Are We Now?
Bioassays have been an area of contention and discussion for decades. The understanding of the relationship between potency, biological activity and mechanism of action always seems to lead to dialogue with regulators, even today…
Potency Assays for Engineered Cell Therapies – Challenges and Opportunities
Engineered cellular therapy products are among the more complex of immunotherapeutic modalities because they are living drugs. Cell-based potency assays are essential to demonstrate that drug product activity is linked to biological critical quality attributes…
Potency Assays for Anti-virus Monoclonal Abs
Viral pathogens can cause wide-spread pandemics (influenza type A, SARS-CoV-2), may have high mortality rates (Ebola virus) and pose enormous health and socioeconomic risks. Certain viruses can also be used as agents for bioterrorism…
